Immunosuppressive Strategies to Improve Outcomes of Kidney Transplantation

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 377-392

  Tang, Ignatius Y ^a   Meier Kriesche, Herwig Ulf ^b   Kaplan, Bruce ^c  

^a Section of Nephrology   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

allograft survival; Antibody induction; cyclosporine; mycophenolate; renal function; sirolimus; steroid withdrawal; tacrolimus

Indexed keywords

ANTITAC; ATELEZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; SIROLIMUS PLUS TACROLIMUS; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 34347268366     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.002     Document Type: Article

References (81)

1. Meier-Kriesche H.-U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
2. Gourishankar S., Hunsicker L.G., Ihangri G.S., et al. The stability of the GFR after renal transplantation is improving. J Am Soc Nephrol 14 (2003) 2387-2394
3. Kasiske B.L., Gaston R.S., Gourishankar S., et al. Long-term deterioration of kidney allograft function. Am J Transplant 5 (2005) 1405-1414
4. Keith D.S., DeMattos A., Golconda M., et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 16 (2005) 1512-1521
5. Meier-Kriesche H.-U., Schold J.D., and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 4 (2004) 1289-1295
6. Vincenti F., de Andres A., Becker T., et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 19 (2006) 446-457
7. Mourad G., Garrigue V., Squifflet J.-P., et al. Induction versus non-induction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 72 (2001) 1050-1055
8. Hardinger K.L., Schnitzler M.A., Miller B., et al. Five-year follow up of rabbit ATG versus ATGAM induction in adult renal transplantation. Transplantation 78 (2004) 136-141
9. Nashan B., Moore R., Amlot P., et al., CHIB 201 International Study Group. Randomized trial of basiliximab versus placebo for control of cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193-1198
10. Kahan B.D., Rajagopalan P.R., Hall M., and United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 7 (1999) 276-284
11. Pontecelli G., Yussim A., Cambi V., et al. A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261-1267
12. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37-43
13. Vincenti F., Kirkman R., Light S., et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161-165
14. Nashan B., Light S., Hardie I., et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 67 (1999) 110-115
15. Adu D., Cockwell P., Ives N.J., et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials. BMJ 326 (2003) 789-793
16. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584-590
17. Lecranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin for prevention of acute renal allograft rejection. Am J Transplant 2 (2002) 48-51
18. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acuter renal allograft rejection. Transplantation 72 (2001) 1915-1919
19. Brennan D.C., Daller J.A., Lake K.D., et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967-1977
20. Haririan A., Morawski K., Sillix D.H., et al. Induction therapy with basiliximab versus rabbit ATG in African-American kidney transplant recipients. Transplantation 79 (2005) 716-721
21. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing and newer immune-monitoring. Transplantation 80 (2005) 457-465
22. Meier-Kriesche H.-U., Li S., Grussner R.W.G., et al. Immunosuppression: evolution in practice and trends 1994-2004. Am J Transplant 6 (2006) 1111-1131
23. Kramer B.K., Montagnino G., Del Castillo D., et al. Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 20 (2005) 968-973
24. Vincenti F., Jensik S.G., Filo R.S., et al. A long-term comparison of tacrolimus (FK 506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at 5 years. Transplantation 73 (2002) 775-782
25. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69 (2000) 834-841
26. Ahsan N., Johnson C., Gonwa T., et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 72 (2001) 245-250
27. Gonwa T., Johnson C., Ahsan N., et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75 (2003) 2048-2053
28. Kaplan B., Schold J.D., and Meier-Kriesche H.U. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 14 (2003) 2980-2984
29. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345 (1995) 1321-1325
30. Sollinger H.W., and U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225-232
31. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029-1037
32. Halloran P., Mathew T., Tomlanovic S., et al., The International Mycophenolate Mofetil Renal transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63 (1997) 39-47
33. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil on renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68 (1999) 391-396
34. Mathew T.H., and Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multi-center study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 65 (1998) 1450-1454
35. Ojo A.O., Meier-Kriesche H.-U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405-2409
36. Meier-Kriesche H.-U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African-American renal transplant recipients. J Am Soc Nephrol 11 (2000) 2366-2370
37. MacDonald A.S., and Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271-280
38. Kahan B.D., and Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 356 (2000) 194-202
39. Mendez R., Gonwa T., Yang H.C., et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80 (2005) 303-309
40. Meier-Kriesche H.-U., Steffen B.J., Chu A.H., et al. Sirolimus with Neoral versus mycophenolate mofetil with Neoral is associated with decreased renal allograft survival. Am J Transplant 4 (2004) 2058-20
41. Meier-Kriesche H.-U., Schold J.D., Srinivas T.R., et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5 (2005) 2273-2280
42. Grinyó J.M. Steroid sparing strategies in renal transplantation. Nephrol Dial Transplant 20 (2005) 2028-2031
43. Opelz G., Dohler B., and Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5 (2005) 720-728
44. Vanrenterghem Y., van Hooff J.P., Squifflet J.P., et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5 (2005) 87-95
45. Vincenti F., Monaco A., Grinyó J., et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 3 (2003) 306-311
46. Rostaing L., Cantarovich D., Mourad G., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79 (2005) 807-814
47. Matas A.J., Ramcharan T., Paraskevas S., et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 1 (2001) 278-283
48. Khwaja K., Asolati M., Harmon J., et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 4 (2004) 980-987
49. Khwaja K., Asolati M., Harmon J.V., et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 78 (2004) 1397-1399
50. Kandaswamy R., Melancon J.K., Dunn T., et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am J Transplant 5 (2005) 1529-1536
51. Matas A.J., Kandaswamy R., Gillingham K.J., et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 5 (2005) 2473-2478
52. Kumar M.S.A., Moritz M.J., Saaed M.I., et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 5 (2005) 1976-1985
53. Kumar M.S.A., Heifets M., Moritz M.J., et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 81 (2006) 832-839
54. Smak Gregoor P.J.H., DeSevaux R.L., Ligtenberg G., et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13 (2002) 1365-1373
55. Hazzan M., Buob D., Labalette M., et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 82 (2006) 657-662
56. Schnuelle P., van der Heide J.H., Tegzess A., et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13 (2002) 536-543
57. Abramowicz D., Del Carmen Rial M., Vitko S., et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 16 (2005) 2234-2240
58. Nashan B., Eldberg H., Grinyó J., et al. Cyclosporine sparing with the use of mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients- the CAESAR Study 36 month results. Am J Transplant 6 Suppl 2 (2006) 436
59. Johnson R.W.G., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777-786
60. Oberbauer R., Kreis H., Johnson R.W.G., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 76 (2003) 364-370
61. Kreis H., Oberbauer R., Campistol J.M., et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809-817
62. Mota A., Arias M., Taskinen E.I., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953-961
63. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22-28
64. Vincenti F., Ramos E., Brattstrom C., et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71 (2001) 1282-1287
65. Grinyó J.M., Gil-Vernet S., Cruzado J.M., et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 16 (2003) 820-827
66. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74 (2002) 1070-1076
67. Flechner S.M., Kurian S.M., Solez K., et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4 (2004) 1776-1785
68. Flechner S.M., Goldfarb D., Solez K., et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 83 (2007) 883-892
69. Grinyó J.M., and Cruzado J.M. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 6 (2006) 1991-1999
70. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 77 (2004) 244-251
71. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77 (2004) 252-258
72. Gonwa T., Mendez R., Yang H.C., et al., Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75 (2003) 1213-1220
73. Mendez R., Gonwa T., Yang H.C., et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80 (2005) 303-309
74. Vitko S., Wlodarczyk Z., Kyllonen L., et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 6 (2006) 531-538
75. Gallon L., Perico N., Dimitrov B.D., et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 6 (2006) 1617-1623
76. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6 (2006) 514-522
77. Ekberg H., Tedesco-Silva H., Demirbas A., et al. SYMPHONY-comparing standard immunosuppression to low-dose cyclosporine, tacrolimus, or sirolimus in combination with mycophenolate mofetil, daclizumab and corticosteroids in renal transplantation. Am J Transplant 6 Suppl 2 (2006) 83
78. Ekberg H., Ginyo Josep, Nashan B., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 7 (2007) 560-567
79. Nankwell B.J., Gruenewald S.M., Allen R.D.M., et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 59 (1995) 683-689
80. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
81. Gaspari F., Ferrari S., Stucchi N., et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 4 (2004) 1826-1835